A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study

0579619 - ÚEM 2024 RIV US eng J - Článek v odborném periodiku
Pardini, B. - Ferrero, G. - Tarallo, S. - Gallo, G. - Francavilla, A. - Licheri, N. - Trompetto, M. - Clerico, G. - Senore, P. - Vymetálková, Veronika - Vodičková, Ludmila - Liška, V. - Vyčítal, O. - Levý, O. - Macinga, P. - Hucl, T. - Budinská, E. - Vodička, Pavel - Cordero, F. - Naccarati, A.
A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study.
Gastroenterology. Roč. 165, č. 3 (2023), s. 582-599. ISSN 0016-5085. E-ISSN 1528-0012
Grant CEP: GA ČR(CZ) GA17-16857S; GA ČR(CZ) GA22-05942S; GA MZd(CZ) NV18-03-00199; GA MŠMT LX22NPO5102
Institucionální podpora: RVO:68378041
Klíčová slova: Stool MicroRNAs * Noninvasive Diagnosis * Small RNA Sequencing * Colorectal Cancer * Precancerous Lesions * Machine Learning
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 29.4, rok: 2022
Způsob publikování: Open access
https://www.sciencedirect.com/science/article/pii/S0016508523008119?via%3Dihub

BACKGROUND & AIMS: Fecal tests currently used for colorectal cancer (CRC) screening show limited accuracy in detecting early tumors or precancerous lesions. In this respect, we comprehensively evaluated stool microRNA (miRNA) profiles as biomarkers for noninvasive CRC diagnosis. METHODS: A total of 1273 small RNA sequencing experiments were performed in multiple biospecimens. In a cross-sectional study, miRNA profiles were investigated in fecal samples from an Italian and a Czech cohort (155 CRCs, 87 adenomas, 96 other intestinal diseases, 141 colonoscopy-negative controls). A predictive miRNA signature for cancer detection was defined by a machine learning strategy and tested in additional fecal samples from 141 CRC patients and 80 healthy volunteers. miRNA profiles were compared with those of 132 tumors/adenomas paired with adjacent mucosa, 210 plasma extracellular vesicle samples, and 185 fecal immunochemical test leftover samples. RESULTS: Twenty-five miRNAs showed altered levels in the stool of CRC patients in both cohorts (adjusted P < .05). A 5-miRNA signature, including miR-149-3p, miR-607-5p, miR-1246, miR-4488, and miR-6777-5p, distinguished patients from control individuals (area under the curve [AUC], 0.86, 95% confidence interval [CI], 0.79-0.94) and was validated in an independent cohort (AUC, 0.96, 95% CI, 0.92-1.00). The signature classified control individuals from patients with low-/high-stage tumors and advanced adenomas (AUC, 0.82, 95% CI, 0.71-0.97). Tissue miRNA profiles mirrored those of stool samples, and fecal profiles of different gastrointestinal diseases highlighted miRNAs specifically dysregulated in CRC. miRNA profiles in fecal immunochemical test leftover samples showed good correlation with those of stool collected in preservative buffer, and their alterations could be detected in adenoma or CRC patients. CONCLUSIONS: Our comprehensive fecal miRNome analysis identified a signature accurately discriminating cancer aimed at improving noninvasive diagnosis and screening strategies.
Trvalý link: https://hdl.handle.net/11104/0348441